10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 150 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $151.000 million which beat the analyst consensus estimate of $146.788 million by 2.87 percent. This is a 12.67 percent decrease over sales of $172.900 million the same period last year.